about
Getting it right the first time: recent progress in optimizing antiemetic usage.Safety of Polysorbate 80 in the Oncology Setting.Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomitingIncidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilarHealth-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) ChemotherapyBiosimilars for breast cancer: a review of HER2-targeted antibodies in the United StatesFixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III
P50
Q51738023-CF71E1BE-15B3-4732-84F9-92778D8DD97BQ55405018-642887C1-7F38-4970-940F-B83FD9A56187Q55666180-4FBF7885-A94A-4071-98BD-B1DA4E36BB8CQ57483947-B1470896-7907-4B78-BA34-04F61037962BQ58767839-CD7E82A6-E2A2-4AF1-B62D-E622505DC68FQ64966409-B59D64F9-49AC-42F2-AA6F-9E38FB2C7064Q90257588-FEC70FA6-7A1E-4D8F-A0C1-BB1584381A86Q91671476-B0227B07-6422-408F-84E5-566AF96AC853Q92993034-DC0A2DF3-5D98-41DC-97E0-6E82ADD6613E
P50
description
researcher ORCID ID = 0000-0002-7433-3428
@en
name
Lee S Schwartzberg
@ast
Lee S Schwartzberg
@en
Lee S Schwartzberg
@nl
type
label
Lee S Schwartzberg
@ast
Lee S Schwartzberg
@en
Lee S Schwartzberg
@nl
prefLabel
Lee S Schwartzberg
@ast
Lee S Schwartzberg
@en
Lee S Schwartzberg
@nl
P31
P496
0000-0002-7433-3428